1 published article · Updated continuously
6 trials tracked for bullous pemphigoid: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 34 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Dupilumab has demonstrated significant efficacy in achieving sustained remission at week 36 compared to the control group (4.0% vs. 18.2%, p=0.0250) 1. Additionally, patients treated with dupilumab experienced a statistically significant reduction in peak pruritus scores from baseline to week 36 (-26.7% vs. -51.8%, p=0.0025) 1. However, there was no statistically significant difference between the groups regarding the total cumulative dose of oral corticosteroids (OCS) from baseline to week 36 1.
Efgartigimod PH20 SC showed a reduction in the 24-hour average itch NRS score at week 36 compared to the control group (-4.4 vs. -2.4) 3. While both groups showed similar reductions in BPDAI total activity scores, a higher number of participants achieved an IGA-BP score of 0 while off OCS therapy for at least 8 weeks at week 36 in the efgartigimod group (9 vs. 3) 3.
Omalizumab was associated with a 22.5% decrease in the total body surface area affected by active bullous pemphigoid skin disease from day 0 to week 24 2.
AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
